Evolus (EOLS) to Release Earnings on Tuesday

Evolus (NASDAQ:EOLS) is anticipated to announce its earnings results after the market closes on Tuesday, March 4th. Analysts expect the company to announce earnings of $0.06 per share and revenue of $79.01 million for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Evolus Trading Up 0.9 %

Shares of Evolus stock opened at $14.11 on Tuesday. Evolus has a 1 year low of $9.25 and a 1 year high of $17.82. The company has a debt-to-equity ratio of 20.58, a current ratio of 2.47 and a quick ratio of 2.23. The stock has a market cap of $893.46 million, a PE ratio of -15.51 and a beta of 1.33. The firm has a fifty day moving average price of $12.40 and a 200 day moving average price of $14.05.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on EOLS shares. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 target price on shares of Evolus in a research note on Tuesday, January 21st. Barclays increased their target price on shares of Evolus from $20.00 to $22.00 and gave the stock an “overweight” rating in a research note on Monday, January 27th. Finally, HC Wainwright restated a “buy” rating and issued a $27.00 price target on shares of Evolus in a research note on Friday, February 14th.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.